Kadmon's Rezurock scores surprise FDA nod in chronic graft-versus-host-disease

With a surprise FDA approval Friday afternoon, Kadmon Holdings is on its way to becoming a commercial drugmaker.

The FDA cleared Kadmon’s Rezurock to treat chronic graft-versus-host disease, a serious complication of transplant procedures. Formerly known as belumodsil, the drug is a first-in-class ROCK2 inhibitor—and now Kadmon’s first approved drug.